Clinical trials: Androgenetic Alopecia
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.
Scarring Alopecia, Androgenetic Alopecia
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia.
- Trial name
- NCT05460611
- Testing
- Sciton HALO 1470nm Non-ablative laser
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
This is a first-in-human study of ABS-201, a new investigational medicine, in healthy adult men and women. Its main purpose is to find out whether ABS-201 is safe and well tolerated, as well as to understand how the body…
- Trial name
- NCT07317544
- Testing
- SAD IV Dose 1 - 150mg ABS201 IV Single Dose, ABS-201 SC Multiple Doses
- Where
- 4 sites in Australia
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Absci Pty Ltd.
Androgenetic Alopecia (AGA)
Multi-Omics Insights Into Androgenetic Alopecia
This study utilizes a multi-omics approach to systematically characterize the cellular heterogeneity and spatial architecture of the hair follicle microenvironment in patients with androgenetic alopecia (AGA).
- Trial name
- NCT07603544
- Testing
- Collection of ~2 × 12 mm scalp tissue, Single-cell sequencing and spatial transcriptome sequencing
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Androgenetic Alopecia, Alopecia
THERAVEX® REGENERA Tissue Care Plus for Hair Regeneration and Follicular Microenvironment Modulation
To evaluate the safety and clinical performance of THERAVEX® REGENERA Tissue Care Plus as an adjunctive regenerative support therapy in patients undergoing hair restoration procedures and regenerative scalp treatment protocols.
- Conditions
- Androgenetic Alopecia, Alopecia, Hair Loss, Non-scarring Alopecia
- Trial name
- NCT07615608
- Testing
- Standard Hair Restoration Care
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Biointelligent Technology Systems SL
Androgenetic Alopecia, Androgenic Alopecia
JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil
Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing…
- Trial name
- NCT07563036
- Testing
- Topical Minoxidil 5% Solution, Scalp Punch Biopsy, Tissue JAK2 Protein Measurement by ELISA
- Where
- Egypt
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Kasr El Aini Hospital
Androgenetic Alopecia
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia.
- Trial name
- NCT07490327
- Testing
- AD-303A, AD-3031
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Moogene Medi Co., Ltd
Androgenetic Alopecia
Harnessing Artificial Intelligence for Diagnosing Androgenetic Alopecia: A Training and Validation Study
The aim of this study is to develop and validate deep learning models in diagnosis of male and female pattern hair loss, and assessment of its severity based on clinical and trichoscopic image by handheld dermoscopy and…
- Trial name
- NCT07294313
- Where
- Egypt
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Cairo University
Telogen Effluvium, Androgenetic Alopecia
Clinical Study to Evaluate Effect of Shampoo in Subjects With Hair Loss.
The goal of this observational study is to learn about the effects of anti-hair loss shampoo in subjects over the age of 18 who use shampoo to treat their hair loss caused by telogen effluvium (TE) and androgenetic alopecia…
- Trial name
- NCT07433933
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lacer S.A.
Androgenetic Alopecia (AGA), Chronic Telogen Effluvium
Evaluation of the Dietary Supplement Efficacy Against Hair Loss in Subjects Suffering From Hair Loss
The goal of this study was to learn if dietary supplement in capsules and drinkable works to help hair loss in volunteers with chronic telogen effluvium and androgenetic alopecia and learn about its safety.
- Trial name
- NCT07358403
- Testing
- Dietary supplement capsule use for hair loss, Dietary supplement drinklable use for hair loss
- Where
- Italy
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Lacer S.A.
Androgenetic Alopecia
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
The goal of this clinical trial is to assess the safety of the AH-001 drug substance at concentrations of 0.2%, 0.5%, 1%, and 2% in healthy volunteers and male subjects with androgenetic alopecia (AGA).
- Trial name
- NCT06927960
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
This study is testing CG2001, a new medicine that is applied as a light foam to the scalp and is being developed to treat male-pattern hair loss (androgenetic alopecia). The main goals are to find out: 1.
- Trial name
- NCT07038941
- Testing
- CG2001
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Beijing Dayspring Pharmaceutical Technology Co., Ltd
Androgenetic Alopecia, Pattern Baldness
Evaluation of the Niostem Headset for Hair Growth and Hair Quality
This double-blind, randomized, placebo-controlled clinical trial evaluates the Niostem headset, an electronic device designed to support hair growth, reduce hair loss, and improve hair quality.
- Trial name
- NCT06994819
- Testing
- niostem headset (Active)
- Where
- Germany
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Mane Biotech GmbH
Androgenetic Alopecia
Development and Standardization Methods
The objective of this study is to establish a standardized methodology that integrates various parameters to comprehensively assess and evaluate hair growth and scalp health.
- Trial name
- NCT06802237
- Testing
- Other
- Where
- India
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- NovoBliss Research Pvt Ltd
Alopecia, Androgenetic, Healthy
Assessment of Biological and Biometrological Parameters in Adult Subjects with Androgenetic Alopecia
Androgenetic alopecia is a chronic pathology affecting approximately 50% of men at 50 years old and is characterized by a progressive miniaturization of the hair follicle leading to a localized baldness.
- Trial name
- NCT06854432
- Testing
- Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Androgenetic Alopecia
Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia
Androgenetic alopecia is a common condition affects both genders. Patients of androgenetic alopecia following inclusion criteria will be enrolled after ethical approval and informed consent.
- Trial name
- NCT06239207
- Testing
- Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%), Platelet Rich Plasma
- Where
- Pakistan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Services Hospital, Lahore
Androgenetic Alopecia
Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss
Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss.
- Trial name
- NCT06590779
- Testing
- Aminexil® active+ lotion, Finasteride 1mg
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Androgenetic Alopecia
Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia
The purpose of this study is to determine whether Wharton's Jelly mesenchymal stem cell-derived exosome microneedling on the scalp is an effective treatment for Androgenetic Alopecia (pattern hair loss).
- Trial name
- NCT06482541
- Testing
- 5 billion exosomes and saline solution microneedling, 50 billion exosomes and saline solution microneedling
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Levit Dermatology
Androgenetic Alopecia
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medications for AGA are topical…
- Trial name
- NCT05365360
- Testing
- LaserCap SD, LaserCap HD+
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Arizona